top of page

Kidney

This session aims to provide points of view for assessment of kidney function highlighting available complex in vitro models covering contexts of use for safety and ADME properties. Case studies demonstrating nephrotoxicity assessment using microfluidic device-based and immune-competent kidney models will be presented. Additionally, the CIVM landscape for Kidney will be discussed to address gaps remaining in modeling renal physiology.

Date & Time

Tuesday, December 3, 2024, 10:30 AM ET - 12:00 PM ET

Duration

90 minutes

Agenda

Welcome and Introduction

Tomomi Kiyota (Genentech)

Anna-Karin Sjögren (AstraZeneca)


Overview of Kidney CIVM/MPS: Model Features, Technical Considerations, Functional Readouts, and Relevant COUs

Haysam Ahmed (UCB)


Case Study: Prediction of drug-induced kidney injury by biomarker response in a proximal tubule MPS

Anna-Karin Sjögren (AstraZeneca)


Case Study: Interspecies comparison of drug-induced nephrotoxicity using proximal tubule CIVMs

Tomomi Kiyota (Genentech)


Case Study: Immune-competent kidney CIVM

Manti Guha (Incyte)


Q&A / Discussion

Tomomi Kiyota (Genentech)

Anna-Karin Sjögren (AstraZeneca)

Moderators and Presenters

Tomomi Kiyota, PhD

Senior Principal Scientist

Genentech, Inc.

<h2 class="font_2"><strong>Tomomi Kiyota, PhD</strong></h2> <p class="font_8">Senior Principal Scientist</p> <p class="font_8">Genentech, Inc.</p>

Tomomi (Tomo) Kiyota is conducting hypothesis-driven investigation to de-risk safety concerns of various modalities. Tomo is currently covering a variety of areas in toxicology including, but not limited to, nephrotoxicity, gastrointestinal toxicity, skin toxicity, neurotoxicity, mitochondrial toxicity and hepatotoxicity. Tomo received PhD degree from Kwansei Gakuin University and completed postdoctoral trainings at Florida State University and University of Nebraska Medical Center.

<h2 class="font_2"><strong>Tomomi Kiyota, PhD</strong></h2> <p class="font_8">Senior Principal Scientist</p> <p class="font_8">Genentech, Inc.</p>

Anna-Karin Sjögren, PhD

Director, Clinical Pharmacology & Safety Sciences, CVRM Safety

AstraZeneca

Anna-Karin Sjögren is a DABT certified toxicologist with >10 years of experience of drug discovery in Pharma industry and a PhD in Molecular Medicine. She works as project toxicologist in drug discovery projects, being responsible for safety assessment and mitigation strategies, and she has a good track record of delivering drug candidates into development across multiple modalities. Anna-Karin also leads the in vitro kidney safety strategy to develop and implement novel advanced cell models to investigate drug-induced kidney toxicity, for safety optimizations and mechanistic evaluations. She has a strong publication record, including several papers in the field of in vitro toxicity assessment.

<h2 class="font_2"><strong>Tomomi Kiyota, PhD</strong></h2> <p class="font_8">Senior Principal Scientist</p> <p class="font_8">Genentech, Inc.</p>

Haysam Ahmed, PhD

Principal Scientist

UCB 

Haysam Ahmed currently works as a Principal Scientist in the Inflammatory Rheumatology Department at UCB Biopharma. He is responsible for the development of multiple complex in vitro models/organ-on-chips for (pre)portfolio projects, including kidney, joint and lymph node.

Manti Guha, PhD

Principal Investigator & CIVM Lead

Incyte

​

​

​

​

​

bottom of page